Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
AB Science clinical trials
The registry lists 39 studies whose lead sponsor is AB Science. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated May 6, 2026.
Keep track of what changes. Save the AB Science studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to AB Science.
- AB Science39 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 39 of 39.
- Masitinib in Patients With Mild Alzheimer's DiseaseNot yet recruitingNCT05564169Phase 3
- Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS PatientsNot yet recruitingNCT07174492Phase 3
- AB8939 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT05211570Phase 1/2
- Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS PatientsRecruitingNCT03127267Phase 3
- Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic TreatmentRecruitingNCT04333108Phase 3
- Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple SclerosisSuspendedNCT05441488Phase 3
- Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate CancerCompletedNCT03761225Phase 3
- Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02588677Phase 2/3
- Masitinib in Patients With Mild to Moderate Alzheimer's DiseaseCompletedNCT01872598Phase 3
- Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19Status unknownNCT04622865Phase 2
- Masitinib for the Treatment of Severe Mast Cell Activation SyndromeStatus unknownNCT05449444Phase 2
- Masitinib in Patients With Symptomatic Mild to Moderate COVID-19Status unknownNCT05047783Phase 2
- Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)TerminatedNCT00812240Phase 3
- Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-AB1010 in Healthy Male SubjectsCompletedNCT05200169Early Phase 1
- Masitinib in Treatment of Patients With Severe Persistent Asthma Treated With Oral CorticosteroidsCompletedNCT01449162Phase 3
- Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil LevelsCompletedNCT03771040Phase 3
- Masitinib Plus Gemcitabine in Pancreatic CancerCompletedNCT03766295Phase 3
- Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal CancerCompletedNCT03556956Phase 2/3
- Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer PatientsCompletedNCT02490488Phase 2/3
- Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With ImatinibCompletedNCT01694277Phase 3
- Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-KitTerminatedNCT01280565Phase 3
- Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple SclerosisCompletedNCT01433497Phase 3
- Masitinib in Severe Indolent or Smoldering Systemic MastocytosisCompletedNCT00814073Phase 3
- Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3CompletedNCT00866138Phase 2
- Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal CancerTerminatedNCT02605044Phase 3
- A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple MyelomaTerminatedNCT01470131Phase 3
- Masitinib in Refractory Active Rheumatoid ArthritisTerminatedNCT01410695Phase 2/3
- Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic CancerCompletedNCT00789633Phase 3
- Masitinib in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of RecurrenceTerminatedNCT02009423Phase 3
- Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's DiseaseCompletedNCT00976118Phase 2
- Masitinib in Combination With Methotrexate, in Treatment of Patients With Active Rheumatoid ArthritisCompletedNCT00913432Phase 2
- Efficacy of AB1010 in Patients With Systemic Indolent MastocytosisCompletedNCT00831974Phase 2
- Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid ArthritisCompletedNCT00831922Phase 2
- Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to ImatinibCompletedNCT01506336Phase 2
- Efficacy of Oral AB1010 in Adult Patients With Severe Persistent Corticosteroid Dependent AsthmaCompletedNCT00842270Phase 2
- Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple SclerosisCompletedNCT01450488Phase 2
- Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)CompletedNCT00998751Phase 2
- Masitinib in Patients With Mastocytosis With Handicap and Bearing the D816V MutationCompletedNCT01266369Phase 2
- A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01045577Phase 2